CoolSculpting

ZELTIQ Aesthetics is a medical technology company best known for developing the CoolSculpting system, a leading non-invasive fat reduction treatment. The company's core technology, cryolipolysis, was developed by scientists at Massachusetts General Hospital and utilizes controlled cooling to target and eliminate fat cells without damaging surrounding tissue. Acquired by Allergan in 2017 for approximately $2.4 billion, and subsequently becoming part of AbbVie, ZELTIQ continues to lead the global body contouring market. The CoolSculpting platform is FDA-cleared for various indications, including the treatment of fat in the abdomen, flanks, thighs, and submental area. The system is widely utilized by dermatologists and plastic surgeons as a non-surgical alternative to liposuction. Beyond fat reduction, the company has expanded its portfolio to include muscle toning technologies like CoolTone.